# Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)

> **NCT01657331** · PHASE1,PHASE2 · COMPLETED · sponsor: **Columbia University** · enrollment: 71 (actual)

## Conditions studied

- Hodgkin Lymphoma
- Anaplastic Large Cell Lymphoma

## Interventions

- **DRUG:** Brentuximab Vedotin
- **DRUG:** Bendamustine
- **DRUG:** Neulasta

## Key facts

- **NCT ID:** NCT01657331
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2020-04
- **Final completion:** 2020-04
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2020-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01657331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01657331, "Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01657331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*